About bioventus inc - BVS
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
BVS At a Glance
Bioventus, Inc.
4721 Emperor Boulevard
Durham, North Carolina 27703
| Phone | 1-919-474-6700 | Revenue | 568.09M | |
| Industry | Medical Specialties | Net Income | 22.73M | |
| Sector | Health Technology | Employees | 930 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BVS Valuation
| P/E Current | 27.19 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 22.552 |
| Price to Sales Ratio | 0.903 |
| Price to Book Ratio | 2.712 |
| Price to Cash Flow Ratio | 6.93 |
| Enterprise Value to EBITDA | 7.741 |
| Enterprise Value to Sales | 1.438 |
| Total Debt to Enterprise Value | 0.381 |
BVS Efficiency
| Revenue/Employee | 610,846.237 |
| Income Per Employee | 24,443.011 |
| Receivables Turnover | 4.422 |
| Total Asset Turnover | 0.805 |
BVS Liquidity
| Current Ratio | 1.701 |
| Quick Ratio | 1.188 |
| Cash Ratio | 0.319 |
BVS Profitability
| Gross Margin | 67.319 |
| Operating Margin | 10.306 |
| Pretax Margin | 4.526 |
| Net Margin | 4.001 |
| Return on Assets | 3.221 |
| Return on Equity | 13.692 |
| Return on Total Capital | 4.588 |
| Return on Invested Capital | 4.791 |
BVS Capital Structure
| Total Debt to Total Equity | 169.113 |
| Total Debt to Total Capital | 62.841 |
| Total Debt to Total Assets | 45.548 |
| Long-Term Debt to Equity | 158.679 |
| Long-Term Debt to Total Capital | 58.964 |